ライブ
FierceBiotechAgenus focuses on survival data as 0% response rate triggers primary missFierceBiotechOdyssey charts fresh voyage to public markets after abandoning IPO plans last yearFierceBiotechAstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD winMedtronicWire-free artery assessment tech joins Medtronic in $585M deal - Stock TitanMedtronicPulnovo completes $100m financing round with Medtronic investment - Yahoo FinancePfizerPfizer, Astellas win FDA priority review for Padcev (PFE:NYSE) - Seeking AlphaMedtronicMedtronic, Pulnovo Join Forces On Pulmonary Denervation After $100M Financing - Citeline News & InsightsMedtronicPulnovo Medical: $100 Million Raised From Medtronic For Pulmonary Hypertension And Heart Failure Therapies - Pulse 2.0Merck & Co.TD Waterhouse Canada Inc. Grows Holdings in Merck & Co., Inc. $MRK - MarketBeatSiemens HealthineersScreenPoint Medical raises $16m with continued investment from Siemens Healthineers - Medical Device NetworkMedtronicMedtronic leads $100M financing for artery denervation tech developer Pulnovo Medical - MassDeviceWuXi AppTecHow WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients - Fierce Biotech
Endpoints News 2026年2月27日

Generate:Biomedicines raises $400M IPO, CEO talks about AI's future in drug design

Generate:Biomedicines raises $400M IPO, CEO talks about AI's future in drug design

原文
本文は利用できません。元の情報源をご確認ください。